- Home
- KZR vs RAND Comparison
KZR vs RAND Comparison
Compare KZR & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- RAND
- Stock Information
- Founded
- KZR 2015
- RAND 1969
- Country
- KZR United States
- RAND United States
- Employees
- KZR N/A
- RAND N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- KZR Health Care
- RAND Finance
- Exchange
- KZR Nasdaq
- RAND Nasdaq
- Market Cap
- KZR 54.1M
- RAND 47.5M
- IPO Year
- KZR 2018
- RAND N/A
- Fundamental
- Price
- KZR $6.43
- RAND $18.44
- Analyst Decision
- KZR Hold
- RAND
- Analyst Count
- KZR 2
- RAND 0
- Target Price
- KZR $11.00
- RAND N/A
- AVG Volume (30 Days)
- KZR 61.0K
- RAND 11.9K
- Earning Date
- KZR 11-12-2024
- RAND 11-06-2024
- Dividend Yield
- KZR N/A
- RAND 6.04%
- EPS Growth
- KZR N/A
- RAND 123.39
- EPS
- KZR N/A
- RAND 4.98
- Revenue
- KZR N/A
- RAND $8,351,941.00
- Revenue This Year
- KZR N/A
- RAND N/A
- Revenue Next Year
- KZR N/A
- RAND N/A
- P/E Ratio
- KZR N/A
- RAND $3.90
- Revenue Growth
- KZR N/A
- RAND 16.96
- 52 Week Low
- KZR $5.20
- RAND $12.81
- 52 Week High
- KZR $11.40
- RAND $24.10
- Technical
- Relative Strength Index (RSI)
- KZR 28.75
- RAND 53.52
- Support Level
- KZR $6.80
- RAND $18.67
- Resistance Level
- KZR $7.04
- RAND $24.10
- Average True Range (ATR)
- KZR 0.24
- RAND 1.04
- MACD
- KZR -0.06
- RAND 0.10
- Stochastic Oscillator
- KZR 0.00
- RAND 34.87
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.